{"id":492,"date":"2022-09-29T16:43:23","date_gmt":"2022-09-29T16:43:23","guid":{"rendered":"http:\/\/localhost:10023\/?page_id=492"},"modified":"2026-04-22T11:59:46","modified_gmt":"2026-04-22T15:59:46","slug":"publications","status":"publish","type":"page","link":"https:\/\/praxismedicines.com\/cs\/publications\/","title":{"rendered":"Publications"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-page\" data-elementor-id=\"492\" class=\"elementor elementor-492\" data-elementor-post-type=\"page\">\n\t\t\t\t<div class=\"elementor-element elementor-element-59634b9 e-flex e-con-boxed e-con e-parent\" data-id=\"59634b9\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-34e3535 e-con-full e-flex e-con e-child\" data-id=\"34e3535\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-21d58a6 elementor-widget elementor-widget-heading\" data-id=\"21d58a6\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h1 class=\"elementor-heading-title elementor-size-default\">Publications<\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-5f11a0b9 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"5f11a0b9\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-e79ff6e\" data-id=\"e79ff6e\" data-element_type=\"column\" data-e-type=\"column\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-40db7643 elementor-widget elementor-widget-heading\" data-id=\"40db7643\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\">Scientific Publications &amp; Presentations\u00a0<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-62afdf5 elementor-widget__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"62afdf5\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><span data-contrast=\"auto\">Explore data from our clinical programs across central nervous system disorders, including movement disorders and epilepsy, supported by our precision neuroscience approach.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-30607460 e-n-tabs-none elementor-widget elementor-widget-n-tabs\" data-id=\"30607460\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;tabs_justify_horizontal_tablet&quot;:&quot;center&quot;,&quot;horizontal_scroll&quot;:&quot;disable&quot;}\" data-widget_type=\"nested-tabs.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"e-n-tabs\" data-widget-number=\"811627616\" aria-label=\"Tabs. Open items with Enter or Space, close with Escape and navigate using the Arrow keys.\">\n\t\t\t<div class=\"e-n-tabs-heading\" role=\"tablist\">\n\t\t\t\t\t<button id=\"e-n-tab-title-8116276161\" data-tab-title-id=\"e-n-tab-title-8116276161\" class=\"e-n-tab-title\" aria-selected=\"true\" data-tab-index=\"1\" role=\"tab\" tabindex=\"0\" aria-controls=\"e-n-tab-content-8116276161\" style=\"--n-tabs-title-order: 1;\">\n\t\t\t\t\t\t<span class=\"e-n-tab-title-text\">\n\t\t\t\tUlixacaltamide\t\t\t<\/span>\n\t\t<\/button>\n\t\t\t\t<button id=\"e-n-tab-title-8116276162\" data-tab-title-id=\"e-n-tab-title-8116276162\" class=\"e-n-tab-title\" aria-selected=\"false\" data-tab-index=\"2\" role=\"tab\" tabindex=\"-1\" aria-controls=\"e-n-tab-content-8116276162\" style=\"--n-tabs-title-order: 2;\">\n\t\t\t\t\t\t<span class=\"e-n-tab-title-text\">\n\t\t\t\tRelutrigine\t\t\t<\/span>\n\t\t<\/button>\n\t\t\t\t<button id=\"e-n-tab-title-8116276163\" data-tab-title-id=\"e-n-tab-title-8116276163\" class=\"e-n-tab-title\" aria-selected=\"false\" data-tab-index=\"3\" role=\"tab\" tabindex=\"-1\" aria-controls=\"e-n-tab-content-8116276163\" style=\"--n-tabs-title-order: 3;\">\n\t\t\t\t\t\t<span class=\"e-n-tab-title-text\">\n\t\t\t\tVormatrigine\t\t\t<\/span>\n\t\t<\/button>\n\t\t\t\t<button id=\"e-n-tab-title-8116276164\" data-tab-title-id=\"e-n-tab-title-8116276164\" class=\"e-n-tab-title\" aria-selected=\"false\" data-tab-index=\"4\" role=\"tab\" tabindex=\"-1\" aria-controls=\"e-n-tab-content-8116276164\" style=\"--n-tabs-title-order: 4;\">\n\t\t\t\t\t\t<span class=\"e-n-tab-title-text\">\n\t\t\t\tElsunersen\t\t\t<\/span>\n\t\t<\/button>\n\t\t\t\t<button id=\"e-n-tab-title-8116276165\" data-tab-title-id=\"e-n-tab-title-8116276165\" class=\"e-n-tab-title\" aria-selected=\"false\" data-tab-index=\"5\" role=\"tab\" tabindex=\"-1\" aria-controls=\"e-n-tab-content-8116276165\" style=\"--n-tabs-title-order: 5;\">\n\t\t\t\t\t\t<span class=\"e-n-tab-title-text\">\n\t\t\t\tOther\t\t\t<\/span>\n\t\t<\/button>\n\t\t\t\t\t<\/div>\n\t\t\t<div class=\"e-n-tabs-content\">\n\t\t\t\t<div id=\"e-n-tab-content-8116276161\" role=\"tabpanel\" aria-labelledby=\"e-n-tab-title-8116276161\" data-tab-index=\"1\" style=\"--n-tabs-title-order: 1;\" class=\"e-active elementor-element elementor-element-260245c2 e-con-full e-flex e-con e-child\" data-id=\"260245c2\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-7a27beaf elementor-widget elementor-widget-html\" data-id=\"7a27beaf\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"html.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"container\">\n\n<table class=\"poster-table2\"><colgroup> <col class=\"col-datetime\" \/>  <\/colgroup>\n<thead>\n\n<tr>\n<th class=\"date-header2\">2026 AAN Annual Meeting<\/th>\n\n<\/tr>\n<\/thead>\n<tbody>\n\n<tr>\n<td class=\"poster-number2\" data-label=\"Poster:\"><a href=\"https:\/\/www.praxismedicines.com\/AAN2026-17-002\/?utm_source=landing&utm_medium=poster-flyer&utm_campaign=2026AAN&utm_content=1\" target=\"_blank\">Efficacy and Safety of Ulixacaltamide in Essential Tremor: Topline Phase 3 Results from Essential3 Study 1 (Parallel-Design Study)\n<\/a><\/td>\n\n<\/tr>\n\n<tr>\n<td class=\"poster-number2\" data-label=\"Poster:\"><a href=\"https:\/\/www.praxismedicines.com\/AAN2026-PL5-001\/?utm_source=landing&utm_medium=poster-flyer&utm_campaign=2026AAN&utm_content=14\" target=\"_blank\">Maintenance of Response and Durability of Effect with Ulixacaltamide in Essential Tremor: Topline Phase 3 Results from Essential3 Study 2 (Randomized Withdrawal Study)\n<\/a><\/td>\n\n<\/tr>\n\n<tr>\n<td class=\"poster-number2\" data-label=\"Poster:\"><a href=\"https:\/\/www.praxismedicines.com\/AAN2026-17-003\/?utm_source=landing&utm_medium=poster-flyer&utm_campaign=2026AAN&utm_content=2\" target=\"_blank\">Combined Efficacy and Safety of Ulixacaltamide in Essential Tremor: Topline Results from the Phase 3 Essential3 Program\n<\/a><\/td>\n\n<\/tr>\n<tr>\n<td class=\"poster-number2\" data-label=\"Poster:\"><a href=\"https:\/\/www.praxismedicines.com\/AAN2026-S11-004\/?utm_source=landing&utm_medium=poster-flyer&utm_campaign=2026AAN&utm_content=3\" target=\"_blank\">Automated Quantitative Assessment of Archimedes Spirals in Essential Tremor: Development and Validation of a Regulatory-grade Digital Biomarker Pipeline for the Essential3 Program\n<\/a><\/td>\n\n<\/tr>\n\n<\/tbody>\n<\/table>\n\n<table class=\"poster-table2\"><colgroup> <col class=\"col-datetime\" \/>  <\/colgroup>\n<thead>\n\n<tr>\n<th class=\"date-header2\">2025 AAN Annual Meeting<\/th>\n\n<\/tr>\n<\/thead>\n<tbody>\n\n<tr>\n<td class=\"poster-number2\" data-label=\"Poster:\"><a href=\"\/wp-content\/uploads\/2025\/04\/AAN2025_E3-Prescreener_Poster_QRcode.pdf\" target=\"_blank\">Characteristics of Adult Essential Tremor Patients Seeking Participation in a Decentralized US Clinical Trial:\nPre-Screener Findings from the Essential3 Program Evaluating Efficacy and Safety of Ulixacaltamide\n<\/a><\/td>\n\n<\/tr>\n\n<tr>\n<td class=\"poster-number2\" data-label=\"Poster:\"><a href=\"\/wp-content\/uploads\/2025\/04\/AAN2025_HCPxPatient-Survey_Poster_QRcode.pdf\" target=\"_blank\">Spotlight on Essential Tremor Management and Impact: Results from an Online Survey\nCapturing HCP and Patient Perspectives of Disease Burden\n<\/a><\/td>\n\n<\/tr>\n\n<\/tbody>\n<\/table>\n\n<table class=\"poster-table2\"><colgroup> <col class=\"col-datetime\" \/>  <\/colgroup>\n<thead>\n\n<tr>\n<th class=\"date-header2\">2024 MDS Congress<\/th>\n\n<\/tr>\n<\/thead>\n<tbody>\n\n<tr>\n<td class=\"poster-number2\" data-label=\"Poster:\"><a href=\"\/wp-content\/uploads\/2024\/09\/MDS2024_E3_StudyDesign_Poster_QRcode.pdf\" target=\"_blank\">Essential3: An Innovative Multi-Study Phase 3 Program to Evaluate the Efficacy and Safety of Ulixacaltamide\n<\/a><\/td>\n\n<\/tr>\n\n\n\n\n<\/tbody>\n<\/table>\n\n<table class=\"poster-table2\"><colgroup> <col class=\"col-datetime\" \/>  <\/colgroup>\n<thead>\n\n<tr>\n<th class=\"date-header2\">2024 AAN Annual Meeting<\/th>\n\n<\/tr>\n<\/thead>\n<tbody>\n\n<tr>\n<td class=\"poster-number2\" data-label=\"Poster:\"><a href=\"\/wp-content\/uploads\/2024\/04\/AAN2024_Propranolol_Talk_QRcode.pdf\" target=\"_blank\">Assessing Clinically Meaningful Improvement Associated with Ulixacaltamide Treatment in Adults with Essential Tremor on Concomitant Propranolol: Findings from Essential1<\/a><\/td>\n\n<\/tr>\n\n\n<\/tbody>\n<\/table>\n\n<table class=\"poster-table2\"><colgroup> <col class=\"col-datetime\" \/>  <\/colgroup>\n<thead>\n\n<tr>\n<th class=\"date-header2\">2023 IAPRD Meeting<\/th>\n\n<\/tr>\n<\/thead>\n\n\n<tbody>\n\n<tr>\n<td class=\"poster-number2\" data-label=\"Poster:\"><a href=\"\/wp-content\/uploads\/2023\/09\/Able_IAPRD2023_E1_Readout.pdf\" target=\"_blank\">Essential1: Results from a Phase 2 Trial Evaluating the Tolerability, Safety, and Efficacy of Ulixacaltamide in Adults with Essential Tremor<\/a><\/td>\n\n<\/tr>\n\n\n<\/tbody>\n<\/table>\n\n<table class=\"poster-table2\"><colgroup> <col class=\"col-datetime\" \/>  <\/colgroup>\n<thead>\n\n<tr>\n<th class=\"date-header2\">2023 MDS Congress<\/th>\n\n<\/tr>\n<\/thead>\n\n\n<tbody>\n\n<tr>\n<td class=\"poster-number2\" data-label=\"Poster:\"><a href=\"\/wp-content\/uploads\/2023\/09\/Giroux_MDS2023_E1_MSD_SUBMIT.pdf\" target=\"_blank\">Patient-Focused, Clinically Meaningful Endpoints as Evidence of Improved Outcomes and Durability of Effect Following Ulixacaltamide Treatment in Adults with Essential Tremor: Findings from Essential1<\/a><\/td>\n\n<\/tr>\n\n\n<\/tbody>\n<\/table>\n\n<table class=\"poster-table2\"><colgroup> <col class=\"col-datetime\" \/>  <\/colgroup>\n<thead>\n\n<tr>\n<th class=\"date-header2\">2022 MDS Congress<\/i><\/th>\n\n<\/tr>\n<\/thead>\n\n\n<tbody>\n\n<tr>\n<td class=\"poster-number2\" data-label=\"Poster:\"><a href=\"\/wp-content\/uploads\/2023\/09\/Olhaye-et-al_MDS2022_944-221_Abstract-951_QRcode.pdf\" target=\"_blank\">A Phase 2 Clinical Trial Evaluating the Efficacy, Safety, Tolerabitlity, and Pharmacokinetics of PRAX-944 in Adults with Essential Tremor<\/a><\/td>\n\n<\/tr>\n\n<tr>\n<td class=\"poster-number2\" data-label=\"Poster:\"><a href=\"\/wp-content\/uploads\/2023\/09\/Olhaye-et-al_MDS2022_Essential1_Abstract-950_QRcode.pdf\" target=\"_blank\">A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of PRAX-944 for the Treatment of Essential Tremor<\/a><\/td>\n\n<\/tr>\n<tr>\n<td class=\"poster-number2\" data-label=\"Poster:\"><a href=\"\/wp-content\/uploads\/2023\/09\/Vetterick-et-al_MDS2022_Claims_Abstract-968_QRcode.pdf\" target=\"_blank\">The Hidden Disease Burden and Treatment Experience of Patients with Essential Tremor: A Retrospective US Claims Analysis<\/a><\/td>\n\n<\/tr>\n<\/tbody>\n<\/table>\n\n<table class=\"poster-table2\"><colgroup> <col class=\"col-datetime\" \/>  <\/colgroup>\n<thead>\n\n<tr>\n<th class=\"date-header2\">Ulixacaltamide Translational Findings in <i>Movement Disorders<\/i><\/th>\n\n<\/tr>\n<\/thead>\n\n\n<tbody>\n\n<tr>\n<td class=\"poster-number2\" data-label=\"Poster:\"><a href=\"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/epdf\/10.1002\/mds.28969 \" target=\"_blank\">Translational Pharmacology of PRAX-944, a Novel T-Type Calcium Channel Blocker in Development for the Treatment of Essential Tremor<\/a><\/td>\n\n<\/tr>\n\n<\/tbody>\n<\/table>\n\n<table class=\"poster-table2\"><colgroup> <col class=\"col-datetime\" \/>  <\/colgroup>\n<thead>\n\n<tr>\n<th class=\"date-header2\">ET Claims Analysis in <i>Advances in Therapy<\/i><\/th>\n\n<\/tr>\n<\/thead>\n\n\n<tbody>\n\n<tr>\n<td class=\"poster-number2\" data-label=\"Poster:\"><a href=\"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02318-8.pdf?pdf=button \" target=\"_blank\">The Hidden Burden of Disease and Treatment Experiences of Patients with Essential Tremor: A Retrospective Claims Data Analysis<\/a><\/td>\n\n<\/tr>\n\n<\/tbody>\n<\/table>\n\n<table class=\"poster-table2\"><colgroup> <col class=\"col-datetime\" \/>  <\/colgroup>\n<thead>\n\n<tr>\n<th class=\"date-header2\">TTCC Mechanistic Review in <i>Annals of Clinical and Translational Neurology<\/th>\n\n<\/tr>\n<\/thead>\n\n\n<tbody>\n\n<tr>\n<td class=\"poster-number2\" data-label=\"Poster:\"><a href=\"https:\/\/onlinelibrary.wiley.com\/doi\/epdf\/10.1002\/acn3.51735\" target=\"_blank\">T-type Calcium Channels as Therapeutic Targets in Essential Tremor and Parkinson's Disease<\/a><\/td>\n\n<\/tr>\n\n<\/tbody>\n<\/table>\n\n<\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div id=\"e-n-tab-content-8116276162\" role=\"tabpanel\" aria-labelledby=\"e-n-tab-title-8116276162\" data-tab-index=\"2\" style=\"--n-tabs-title-order: 2;\" class=\" elementor-element elementor-element-35a69c2d e-con-full e-flex e-con e-child\" data-id=\"35a69c2d\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-6b34c26b elementor-widget elementor-widget-html\" data-id=\"6b34c26b\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"html.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"container\">\n\n<table class=\"poster-table2\"><colgroup> <col class=\"col-datetime\" \/>  <\/colgroup>\n<thead>\n\n<tr>\n<th class=\"date-header2\">2026 AAN Annual Meeting<\/th>\n\n<\/tr>\n<\/thead>\n<tbody>\n\n<tr>\n<td class=\"poster-number2\" data-label=\"Poster:\"><a href=\"https:\/\/www.praxismedicines.com\/AAN2026-10-010\/?utm_source=landing&utm_medium=poster-flyer&utm_campaign=2026AAN&utm_content=9\" target=\"_blank\">Efficacy and Safety of Relutrigine in Pediatric Participants with SCN2A- and SCN8A-related Developmental and Epileptic Encephalopathies: Pivotal EMBOLD Cohort 2 Study\n<\/a><\/td>\n\n<\/tr>\n\n<tr>\n<td class=\"poster-number2\" data-label=\"Poster:\"><a href=\"https:\/\/www.praxismedicines.com\/AAN2026-10-009\/?utm_source=landing&utm_medium=poster-flyer&utm_campaign=2026AAN&utm_content=10\" target=\"_blank\">EMERALD: A Phase 3, Randomized, Multi-center, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Relutrigine in Participants with Developmental and Epileptic Encephalopathies\n<\/a><\/td>\n\n<\/tr>\n\n\n<\/tbody>\n<\/table>\n\n<table class=\"poster-table2\"><colgroup> <col class=\"col-datetime\" \/>  <\/colgroup>\n<thead>\n\n<tr>\n<th class=\"date-header2\">2025 AES Annual Meeting<\/th>\n\n<\/tr>\n<\/thead>\n<tbody>\n\n<tr>\n<td class=\"poster-number2\" data-label=\"Poster:\"><a href=\"https:\/\/praxismedicines.com\/AES138\/?utm_source=corporatesite&utm_medium=resourcespage&utm_campaign=AES2025&utm_content=2\" target=\"_blank\">Relutrigine Demonstrates Disease-Modifying Impact in DEEs: Results from the EMBOLD Study<\/a><\/td>\n\n<\/tr>\n<tr>\n<td class=\"poster-number2\" data-label=\"Poster:\"><a href=\"https:\/\/praxismedicines.com\/AES3341\/?utm_source=corporatesite&utm_medium=resourcespage&utm_campaign=AES2025&utm_content=5\" target=\"_blank\">Preclinical Findings of Relutrigine, a Functional State Sodium Channel Modulator, Point\nto Anticonvulsant Potential in Dravet Syndrome with Greater Potency than Fenfluramine<\/a><\/td>\n\n<\/tr>\n\n\n\n<\/tbody>\n<\/table>\n\n<table class=\"poster-table2\"><colgroup> <col class=\"col-datetime\" \/>  <\/colgroup>\n<thead>\n\n<tr>\n<th class=\"date-header2\">2025 IEC Meeting<\/th>\n\n<\/tr>\n<\/thead>\n<tbody>\n\n<tr>\n<td class=\"poster-number2\" data-label=\"Poster:\"><a href=\"\/p157_gil-nagel_iec2025_embold-topline\/?utm_source=corporatesite&utm_medium=schedule&utm_campaign=IEC2025&utm_content=2\" target=\"_blank\">Relutrigine Demonstrates Robust Seizure Reduction and Seizure Freedom in DEEs: Results from the EMBOLD Study<\/a><\/td>\n\n<\/tr>\n<tr>\n<td class=\"poster-number2\" data-label=\"Poster:\"><a href=\"\/p158_spar_iec2025_nz-eap\/?utm_source=corporatesite&utm_medium=schedule&utm_campaign=IEC2025&utm_content=3\" target=\"_blank\">Emergency Use Case of Relutrigine, a Functional State Sodium Channel Modulator, in an Infant with SCN2A-DEE and Refractory Status Epilepticus<\/a><\/td>\n\n<\/tr>\n<tr>\n<td class=\"poster-number2\" data-label=\"Poster:\"><a href=\"\/p505_kamireddy_iec2025_emerald\/?utm_source=corporatesite&utm_medium=schedule&utm_campaign=IEC2025&utm_content=5\" target=\"_blank\">EMERALD: A Phase 3, Randomized, Multi-Center, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Relutrigine in Participants with Developmental and Epileptic Encephalopathies<\/a><\/td>\n\n<\/tr>\n\n<tr>\n<td class=\"poster-number2\" data-label=\"Poster:\"><a href=\"\/p212_anderson_iec2025_dravet\/?utm_source=corporatesite&utm_medium=schedule&utm_campaign=IEC2025&utm_content=9\" target=\"_blank\">Preclinical Findings of Relutrigine, a Precision Sodium Channel Modulator, Point to Anticonvulsant Potential in Dravet Syndrome\n<\/a><\/td>\n\n<\/tr>\n\n<\/tbody>\n<\/table>\n\n<table class=\"poster-table2\"><colgroup> <col class=\"col-datetime\" \/>  <\/colgroup>\n<thead>\n\n<tr>\n<th class=\"date-header2\">2023 IEC Meeting<\/th>\n\n<\/tr>\n<\/thead>\n<tbody>\n\n<tr>\n<td class=\"poster-number2\" data-label=\"Poster:\"><a href=\"\/wp-content\/uploads\/2023\/09\/IEC2023_562-In-Vivo_Final_QRcode.pdf\" target=\"_blank\">PRAX-562 is a Well-Tolerated, Next Generation Anti-Seizure Small Molecule with Broad Anticonvulsant Activity in Multiple DEE Mouse Models<\/a><\/td>\n\n<\/tr>\n<tr>\n<td class=\"poster-number2\" data-label=\"Poster:\"><a href=\"\/wp-content\/uploads\/2023\/09\/IEC2023_562-101_Final_QRcode.pdf\" target=\"_blank\">PRAX-562-101: A Phase1 Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Food Effect of PRAX-562 in Healthy Volunteers<\/a><\/td>\n\n<\/tr>\n<tr>\n<td class=\"poster-number2\" data-label=\"Poster:\"><a href=\"\/wp-content\/uploads\/2024\/07\/IEC2023_562-102_Final_QRcode.pdf\" target=\"_blank\">PRAX-562-102: A Phase1 Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PRAX-562 in Healthy Volunteers<\/a><\/td>\n\n<\/tr>\n\n<\/tbody>\n<\/table>\n\n<table class=\"poster-table2\"><colgroup> <col class=\"col-datetime\" \/>  <\/colgroup>\n<thead>\n\n<tr>\n<th class=\"date-header2\">2022 AES Annual Meeting and Behind the Seizure Scientific Exhibit<\/th>\n\n<\/tr>\n<\/thead>\n\n\n<tbody>\n\n<tr>\n<td class=\"poster-number2\" data-label=\"Poster:\"><a href=\"\/wp-content\/uploads\/2023\/09\/Dalby_AES2022_SCN2A_Final_Approved_QR.pdf\" target=\"_blank\">Disease Impact and Burden in Patients with SCN2A-Related Developmental and Epileptic Encephalopathy<\/a><\/td>\n\n<\/tr>\n\n\n<tr>\n<td class=\"poster-number2\" data-label=\"Poster:\"><a href=\"\/wp-content\/uploads\/2023\/09\/Pfister_AES2022-SCN8A_Final_Approved_QR.pdf\" target=\"_blank\">A Novel Approach to Assess the Impact of Disease in Patients with SCN8A-Related Developmental and Epileptic Encephalopathy<\/a><\/td>\n\n<\/tr>\n\n\n<\/tbody>\n<\/table>\n\n<table class=\"poster-table2\"><colgroup> <col class=\"col-datetime\" \/>  <\/colgroup>\n<thead>\n\n<tr>\n<th class=\"date-header2\">2021 AES Annual Meeting<\/th>\n\n<\/tr>\n<\/thead>\n\n\n<tbody>\n\n<tr>\n<td class=\"poster-number2\" data-label=\"Poster:\"><a href=\"\/wp-content\/uploads\/2023\/09\/Densmore_SeizureExhibit_poster_final.pdf\" target=\"_blank\">Patient-guided Approaches to Drug Development in SCN8A-related Epilepsy: Insights from a Caregiver Survey of Feeding & Medication Formulation Priorities<\/a><\/td>\n\n<\/tr>\n\n\n<\/tbody>\n<\/table>\n\n<table class=\"poster-table2\"><colgroup> <col class=\"col-datetime\" \/>  <\/colgroup>\n<thead>\n\n<tr>\n<th class=\"date-header2\">PRAX-562 Pharmacology in <i>Epilepsia<\/i><\/th>\n\n<\/tr>\n<\/thead>\n\n\n<tbody>\n\n<tr>\n<td class=\"poster-number2\" data-label=\"Poster:\"><a href=\"https:\/\/onlinelibrary.wiley.com\/doi\/epdf\/10.1111\/epi.17149\" target=\"_blank\">The Novel Persistent Sodium Current Inhibitor PRAX-562 has Potent Anticonvulsant Activity with Improved Protective Index Relative to Standard of Care Sodium Channel Blockers<\/a><\/td>\n\n<\/tr>\n\n\n<\/tbody>\n<\/table>\n\n\n<\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div id=\"e-n-tab-content-8116276163\" role=\"tabpanel\" aria-labelledby=\"e-n-tab-title-8116276163\" data-tab-index=\"3\" style=\"--n-tabs-title-order: 3;\" class=\" elementor-element elementor-element-4fb999d2 e-con-full e-flex e-con e-child\" data-id=\"4fb999d2\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-175e2c43 elementor-widget elementor-widget-html\" data-id=\"175e2c43\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"html.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"container\">\n\n<table class=\"poster-table2\"><colgroup> <col class=\"col-datetime\" \/>  <\/colgroup>\n<thead>\n\n<tr>\n<th class=\"date-header2\">2026 AAN Annual Meeting<\/th>\n\n<\/tr>\n<\/thead>\n<tbody>\n\n<tr>\n<td class=\"poster-number2\" data-label=\"Poster:\"><a href=\"https:\/\/www.praxismedicines.com\/AAN2026-10-008\/?utm_source=landing&utm_medium=poster-flyer&utm_campaign=2026AAN&utm_content=4\" target=\"_blank\">Updates from the First-in-human Phase 1 Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Food Effect of Vormatrigine in Healthy Participants\n<\/a><\/td>\n\n<\/tr>\n\n<tr>\n<td class=\"poster-number2\" data-label=\"Poster:\"><a href=\"https:\/\/www.praxismedicines.com\/AAN2026-11-007\/?utm_source=landing&utm_medium=poster-flyer&utm_campaign=2026AAN&utm_content=5\" target=\"_blank\">High Seizure Burden and Limited Treatment Persistence in Epilepsy: Findings from the EMPOWER Observational Study and a US Real-world Claims Analysis\n<\/a><\/td>\n\n<\/tr>\n<tr>\n<td class=\"poster-number2\" data-label=\"Poster:\"><a href=\"https:\/\/www.praxismedicines.com\/AAN2026-10-003\/?utm_source=landing&utm_medium=poster-flyer&utm_campaign=2026AAN&utm_content=6\" target=\"_blank\">Vormatrigine Rapidly Reduces Seizures in Adults with Treatment-resistant Epilepsy: Results from the RADIANT Study\n<\/a><\/td>\n\n<\/tr>\n\n<tr>\n<td class=\"poster-number2\" data-label=\"Poster:\"><a href=\"https:\/\/www.praxismedicines.com\/AAN2026-11-010\/?utm_source=landing&utm_medium=poster-flyer&utm_campaign=2026AAN&utm_content=7\" target=\"_blank\">POWER1 \u2013 A Double-blind, Randomized, Multicenter Phase 2\/3 Study Evaluating the Efficacy and Safety of Vormatrigine in Adults with Focal Onset Seizures\n<\/a><\/td>\n\n<\/tr>\n\n<\/tbody>\n<\/table>\n\n<table class=\"poster-table2\"><colgroup> <col class=\"col-datetime\" \/>  <\/colgroup>\n<thead>\n\n<tr>\n<th class=\"date-header2\">2025 AES Annual Meeting<\/th>\n\n<\/tr>\n<\/thead>\n<tbody>\n\n<tr>\n<td class=\"poster-number2\" data-label=\"Poster:\"><a href=\"https:\/\/praxismedicines.com\/AES1503\/?utm_source=corporatesite&utm_medium=resourcespage&utm_campaign=AES2025&utm_content=1\" target=\"_blank\">Vormatrigine Rapidly Reduces Seizures in Adults with Treatment-Resistant\nEpilepsy: Results from the RADIANT Study<\/a><\/td>\n\n<\/tr>\n<tr>\n<td class=\"poster-number2\" data-label=\"Poster:\"><a href=\"https:\/\/praxismedicines.com\/AES336\/?utm_source=corporatesite&utm_medium=resourcespage&utm_campaign=AES2025&utm_content=6\" target=\"_blank\">Vormatrigine Exhibits a Favorable Drug-Drug Interaction Profile Supporting\nBroad Combination Use with Antiseizure Medications<\/a><\/td>\n\n<\/tr>\n<tr>\n<td class=\"poster-number2\" data-label=\"Poster:\"><a href=\"https:\/\/praxismedicines.com\/AES337\/?utm_source=corporatesite&utm_medium=schedule&utm_campaign=AES2025&utm_content=7\" target=\"_blank\">Epilepsy Monitoring of Prospective Seizure Observations with Electronic Records\n(EMPOWER): A Novel, Prospective, Large-scale, Observational Study Designed to\nBetter Understand the Patient Journey<\/a><\/td>\n\n<\/tr>\n\n\n\n<\/tbody>\n<\/table>\n\n<table class=\"poster-table2\"><colgroup> <col class=\"col-datetime\" \/>  <\/colgroup>\n<thead>\n\n<tr>\n<th class=\"date-header2\">2025 IEC Meeting<\/th>\n\n<\/tr>\n<\/thead>\n<tbody>\n\n<tr>\n<td class=\"poster-number2\" data-label=\"Poster:\"><a href=\"\/p196_hansen_iec2025_radiant-topline\/?utm_source=corporatesite&utm_medium=schedule&utm_campaign=IEC2025&utm_content=1\" target=\"_blank\">Vormatrigine Rapidly Reduces Seizures in Adults with Treatment-Resistant Epilepsy: Results from the RADIANT Open Label Phase 2 Study<\/a><\/td>\n\n<\/tr>\n<tr>\n<td class=\"poster-number2\" data-label=\"Poster:\"><a href=\"\/p225_steidle_iec2025_power1\/?utm_source=corporatesite&utm_medium=schedule&utm_campaign=IEC2025&utm_content=10\" target=\"_blank\">POWER1 \u2013 A Double-Blind, Randomized, Multicenter Phase 2\/3 Study Evaluating the Efficacy and Safety of Vormatrigine in Adults with Focal Onset Seizures<\/a><\/td>\n\n<\/tr>\n<tr>\n<td class=\"poster-number2\" data-label=\"Poster:\"><a href=\"\/p248_petrou_iec2025_prax-628-ph1-update\/?utm_source=corporatesite&utm_medium=schedule&utm_campaign=IEC2025&utm_content=11\" target=\"_blank\">Updates from the First-in-human Phase 1 Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Food Effect of Vormatrigine in Healthy Participants<\/a><\/td>\n\n<\/tr>\n\n<tr>\n<td class=\"poster-number2\" data-label=\"Poster:\"><a href=\"\/p202_kahlig_iec2025_628-audiogenic\/?utm_source=corporatesite&utm_medium=schedule&utm_campaign=IEC2025&utm_content=8\" target=\"_blank\">Vormatrigine Demonstrates Potent Antiseizure Activity Across Three Acute Models with Highest Predictive Validity for Focal Onset Seizures<\/a><\/td>\n\n<\/tr>\n\n\n\n<\/tbody>\n<\/table>\n\n<table class=\"poster-table2\"><colgroup> <col class=\"col-datetime\" \/>  <\/colgroup>\n<thead>\n\n<tr>\n<th class=\"date-header2\">2024 EEC Meeting<\/th>\n\n<\/tr>\n<\/thead>\n<tbody>\n\n<tr>\n<td class=\"poster-number2\" data-label=\"Poster:\"><a href=\"\/wp-content\/uploads\/2024\/09\/Hansen_EEC2024_628-PK_2_QRcode.pdf\" target=\"_blank\">Pharmacokinetics, Tolerability and Cardiac Safety for PRAX-628, a Precision Medicine Therapeutic Set to Initiate Registration Enabling Studies for Focal Onset Seizures<\/a><\/td>\n\n<\/tr>\n\n\n<\/tbody>\n<\/table>\n\n<table class=\"poster-table2\"><colgroup> <col class=\"col-datetime\" \/>  <\/colgroup>\n<thead>\n\n<tr>\n<th class=\"date-header2\">2023 AAN Annual Meeting<\/th>\n\n<\/tr>\n<\/thead>\n\n\n<tbody>\n\n<tr>\n<td class=\"poster-number2\" data-label=\"Poster:\"><a href=\"\/wp-content\/uploads\/2023\/09\/Kahlig_AAN2023_628-In-Vitro_Final_Approved.pdf\" target=\"_blank\">PRAX-628: A Novel Sodium Channel Blocker with Greater Potency and Activity Dependence Compared to Standard of Care<\/a><\/td>\n\n<\/tr>\n\n\n<\/tbody>\n<\/table>\n\n<table class=\"poster-table2\"><colgroup> <col class=\"col-datetime\" \/>  <\/colgroup>\n<thead>\n\n<tr>\n<th class=\"date-header2\">Vormatrigine Summary in <i>Epilepsia<\/th>\n\n<\/tr>\n<\/thead>\n\n\n<tbody>\n\n<tr>\n<td class=\"poster-number2\" data-label=\"Poster:\"><a href=\"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/epi.18056\" target=\"_blank\">Progress report on new medications for seizures and epilepsy: A summary of the 17th Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII). I. Drugs in preclinical and early clinical development<\/a><\/td>\n\n<\/tr>\n\n\n<\/tbody>\n<\/table>\n\n\n<\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div id=\"e-n-tab-content-8116276164\" role=\"tabpanel\" aria-labelledby=\"e-n-tab-title-8116276164\" data-tab-index=\"4\" style=\"--n-tabs-title-order: 4;\" class=\" elementor-element elementor-element-532c0798 e-con-full e-flex e-con e-child\" data-id=\"532c0798\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-31d34ec8 elementor-widget elementor-widget-html\" data-id=\"31d34ec8\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"html.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"container\">\n\n<table class=\"poster-table2\"><colgroup> <col class=\"col-datetime\" \/>  <\/colgroup>\n<thead>\n\n<tr>\n<th class=\"date-header2\">2026 AAN Annual Meeting<\/th>\n\n<\/tr>\n<\/thead>\n<tbody>\n\n<tr>\n<td class=\"poster-number2\" data-label=\"Poster:\"><a href=\"https:\/\/www.praxismedicines.com\/AAN2026-11-009\/?utm_source=landing&utm_medium=poster-flyer&utm_campaign=2026AAN&utm_content=8\" target=\"_blank\">Complementary Antisense Oligonucleotide Treatment and Precision Sodium Channel Modulation for Early Onset SCN2A Developmental and Epileptic Encephalopathy: Emergency Use Case in a Preterm Infant with Refractory Status Epilepticus\n<\/a><\/td>\n\n<\/tr>\n\n\n<tr>\n<td class=\"poster-number2\" data-label=\"Poster:\"><a href=\"https:\/\/www.praxismedicines.com\/AAN2026-S29-010\/?utm_source=landing&utm_medium=poster-flyer&utm_campaign=2026AAN&utm_content=15\" target=\"_blank\">Clinical Updates from the Elsunersen Emergency Use Program: A Novel ASO for Treatment of Early Onset SCN2A Developmental and Epileptic Encephalopathy\n<\/a><\/td>\n\n<\/tr>\n<\/tbody>\n<\/table>\n<table class=\"poster-table2\"><colgroup> <col class=\"col-datetime\" \/>  <\/colgroup>\n<thead>\n\n<tr>\n<th class=\"date-header2\">2025 AES Annual Meeting<\/th>\n\n<\/tr>\n<\/thead>\n<tbody>\n\n<tr>\n<td class=\"poster-number2\" data-label=\"Poster:\"><a href=\"https:\/\/praxismedicines.com\/AES3303\/?utm_source=corporatesite&utm_medium=resourcespage&utm_campaign=AES2025&utm_content=4\" target=\"_blank\">Complementary Antisense Oligonucleotide Treatment and Precision Sodium\nChannel Modulation for Early Onset SCN2A DEE: Emergency Use Cases in a\nPreterm Infant with Refractory Status Epilepticus<\/a><\/td>\n\n<\/tr>\n\n\n\n<\/tbody>\n<\/table>\n\n<table class=\"poster-table2\"><colgroup> <col class=\"col-datetime\" \/>  <\/colgroup>\n<thead>\n\n<tr>\n<th class=\"date-header2\">2025 IEC Meeting<\/th>\n\n<\/tr>\n<\/thead>\n<tbody>\n\n<tr>\n<td class=\"poster-number2\" data-label=\"Poster:\"><a href=\"\/p249_petrou_iec2025_elsunersen-global-eap\/?utm_source=corporatesite&utm_medium=schedule&utm_campaign=IEC2025&utm_content=12\" target=\"_blank\">Clinical Updates from the Elsunersen Emergency Use Program: A Novel ASO for Treatment of Early Onset SCN2A Developmental and Epileptic Encephalopathy<\/a><\/td>\n\n<\/tr>\n<tr>\n<td class=\"poster-number2\" data-label=\"Poster:\"><a href=\"\/p504_zaddach_iec2025_germany-case-study\/?utm_source=corporatesite&utm_medium=schedule&utm_campaign=IEC2025&utm_content=4\" target=\"_blank\">Complementary Antisense Oligonucleotide Treatment and Precision Sodium Channel Modulation for Early Onset SCN2A Developmental and Epileptic Encephalopathy: Emergency Use Cases in a Preterm Infant with Refractory Status Epilepticus<\/a><\/td>\n\n<\/tr>\n\n\n\n<\/tbody>\n<\/table>\n\n<table class=\"poster-table2\"><colgroup> <col class=\"col-datetime\" \/>  <\/colgroup>\n<thead>\n\n<tr>\n<th class=\"date-header2\">2024 EEC Meeting<\/th>\n\n<\/tr>\n<\/thead>\n<tbody>\n\n<tr>\n<td class=\"poster-number2\" data-label=\"Poster:\"><a href=\"\/wp-content\/uploads\/2024\/09\/Frizzo_EEC2024_EMBRAVE_Talk_QRcode.pdf\" target=\"_blank\">Significant Seizure Reduction in Pediatric Participants with Early Onset SCN2A Developmental and Epileptic Encephalopathy following Treatment with Elsunersen, a Novel Antisense Oligonucleotide: Findings from the EMBRAVE Study<\/a><\/td>\n\n<\/tr>\n\n\n<\/tbody>\n<\/table>\n\n<table class=\"poster-table2\"><colgroup> <col class=\"col-datetime\" \/>  <\/colgroup>\n<thead>\n\n<tr>\n<th class=\"date-header2\">2023 Oligonucleotides for CNS Meeting<\/th>\n\n<\/tr>\n<\/thead>\n\n\n<tbody>\n\n<tr>\n<td class=\"poster-number2\" data-label=\"Poster:\"><a href=\"\/wp-content\/uploads\/2023\/09\/Kahlig-Oligo-for-CNS-2023.pdf\" target=\"_blank\">Leveraging Preclinical Models To Inform Clinical Trial Strategy in SCN2A Developmental and Epileptic Encephalopathy <\/a><\/td>\n\n<\/tr>\n\n\n<\/tbody>\n<\/table>\n\n<table class=\"poster-table2\"><colgroup> <col class=\"col-datetime\" \/>  <\/colgroup>\n<thead>\n\n<tr>\n<th class=\"date-header2\">2022 AES Annual Meeting and Behind the Seizure Scientific Exhibit<\/th>\n\n<\/tr>\n<\/thead>\n\n\n<tbody>\n\n<tr>\n<td class=\"poster-number2\" data-label=\"Poster:\"><a href=\"\/wp-content\/uploads\/2023\/09\/Dalby_AES2022_SCN2A_Final_Approved_QR.pdf\" target=\"_blank\">Disease Impact and Burden in Patients with SCN2A-Related Developmental and Epileptic Encephalopathy<\/a><\/td>\n\n<\/tr>\n\n\n<\/tbody>\n<\/table>\n\n<table class=\"poster-table2\"><colgroup> <col class=\"col-datetime\" \/>  <\/colgroup>\n<thead>\n\n<tr>\n<th class=\"date-header2\">2022 Drug Discovery for Ion Channels XXII Meeting<\/i><\/th>\n\n<\/tr>\n<\/thead>\n\n\n<tbody>\n\n<tr>\n<td class=\"poster-number2\" data-label=\"Poster:\"><a href=\"\/wp-content\/uploads\/2023\/09\/Kahlig-DDIC-2022.pdf\" target=\"_blank\">Using Dynamic Action Potential Clamp Modeling of NaV1.2 Variants to Support the Prediction of Clinical Phenotype in DEE<\/a><\/td>\n\n<\/tr>\n\n\n<\/tbody>\n<\/table>\n<table class=\"poster-table2\"><colgroup> <col class=\"col-datetime\" \/>  <\/colgroup>\n<thead>\n\n<tr>\n<th class=\"date-header2\">Elsunersen First-in-Human Case in <i>Nature Medicine<\/i><\/th>\n\n<\/tr>\n<\/thead>\n\n\n<tbody>\n\n<tr>\n<td class=\"poster-number2\" data-label=\"Poster:\"><a href=\"\/wp-content\/uploads\/2025\/04\/2025-Elsunersen-first-in-human-case-in-Nature-Medicine.pdf\" target=\"_blank\">Antisense Oligonucleotide Treatment in a Preterm Infant With Early-Onset SCN2A Developmental and Epileptic Encephalopathy<\/a><\/td>\n\n<\/tr>\n\n\n<\/tbody>\n<\/table>\n\n<\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div id=\"e-n-tab-content-8116276165\" role=\"tabpanel\" aria-labelledby=\"e-n-tab-title-8116276165\" data-tab-index=\"5\" style=\"--n-tabs-title-order: 5;\" class=\" elementor-element elementor-element-48c11059 e-con-full e-flex e-con e-child\" data-id=\"48c11059\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-7cfe82c8 elementor-widget elementor-widget-html\" data-id=\"7cfe82c8\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"html.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"container\">\n<table class=\"poster-table2\"><colgroup> <col class=\"col-datetime\" \/>  <\/colgroup>\n<thead>\n\n<tr>\n<th class=\"date-header2\">2026 AAN Annual Meeting<\/th>\n\n<\/tr>\n<\/thead>\n<tbody>\n\n<tr>\n<td class=\"poster-number2\" data-label=\"Poster:\"><a href=\"https:\/\/www.praxismedicines.com\/AAN2026-11-002\/?utm_source=landing&utm_medium=poster-flyer&utm_campaign=2026AAN&utm_content=11\" target=\"_blank\">PAC-DEE: An Extension of the Praxis Analysis of Concordance Framework for Establishing the Predictive Validity of Preclinical Seizure Models across Broad Developmental and Epileptic Encephalopathies\n<\/a><\/td>\n\n<\/tr>\n\n<tr>\n<td class=\"poster-number2\" data-label=\"Poster:\"><a href=\"https:\/\/www.praxismedicines.com\/AAN2026-14-004\/?utm_source=landing&utm_medium=poster-flyer&utm_campaign=2026AAN&utm_content=12\" target=\"_blank\">PAC-PAIN: Application of the Praxis Analysis of Concordance Framework for Establishing the Predictive Validity of Preclinical Pain Models\n<\/a><\/td>\n\n<\/tr>\n<tr>\n<td class=\"poster-number2\" data-label=\"Poster:\"><a href=\"https:\/\/www.praxismedicines.com\/AAN2026-7-005\/?utm_source=landing&utm_medium=poster-flyer&utm_campaign=2026AAN&utm_content=13\" target=\"_blank\">Evaluating the Therapeutic Potential of Emerging Precision Sodium Channel Modulators in Pain\n<\/a><\/td>\n\n<\/tr>\n\n\n<\/tbody>\n<\/table>\n\n\n<table class=\"poster-table2\"><colgroup> <col class=\"col-datetime\" \/>  <\/colgroup>\n<thead>\n\n<tr>\n<th class=\"date-header2\">2025 AES Annual Meeting<\/th>\n\n<\/tr>\n<\/thead>\n<tbody>\n\n<tr>\n<td class=\"poster-number2\" data-label=\"Poster:\"><a href=\"https:\/\/www.praxismedicines.com\/AES3189\/?utm_source=corporatesite&utm_medium=resourcespage&utm_campaign=AES2025&utm_content=3\" target=\"_blank\"> PAC-DEE: An Extension of the Praxis Analysis of Concordance Framework for Establishing the Predictive Validity of Preclinical Seizure Models across Broad Developmental and Epileptic Encephalopathies<\/a><\/td>\n\n<\/tr>\n\n<\/tbody>\n<\/table>\n\n<table class=\"poster-table2\"><colgroup> <col class=\"col-datetime\" \/>  <\/colgroup>\n<thead>\n\n<tr>\n<th class=\"date-header2\">2025 IEC Meeting<\/th>\n\n<\/tr>\n<\/thead>\n<tbody>\n\n<tr>\n<td class=\"poster-number2\" data-label=\"Poster:\"><a href=\"\/anderson_iec2025_pac-gen-talk\/?utm_source=corporatesite&utm_medium=schedule&utm_campaign=IEC2025&utm_content=7\" target=\"_blank\">Establishing the Predictive Validity of Preclinical Seizure Models in Generalized Epilepsies: An Extension of the Praxis Analysis of Concordance Framework<\/a><\/td>\n\n<\/tr>\n\n\n\n\n<\/tbody>\n<\/table>\n\n<table class=\"poster-table2\"><colgroup> <col class=\"col-datetime\" \/>  <\/colgroup>\n<thead>\n\n<tr>\n<th class=\"date-header2\">2024 EEC Meeting<\/th>\n\n<\/tr>\n<\/thead>\n<tbody>\n\n<tr>\n<td class=\"poster-number2\" data-label=\"Poster:\"><a href=\"\/wp-content\/uploads\/2024\/09\/Hansen_EEC2024_qEEG_2_QRcode.pdf\" target=\"_blank\">A Novel Method to Define an EEG Composite for the Detection of Drug Effects of Next Generation Small Molecules for Epilepsy<\/a><\/td>\n\n<\/tr>\n\n\n<\/tbody>\n<\/table>\n\n<table class=\"poster-table2\"><colgroup> <col class=\"col-datetime\" \/>  <\/colgroup>\n<thead>\n\n<tr>\n<th class=\"date-header2\">2023 SYNGAP1 Conference<\/th>\n\n<\/tr>\n<\/thead>\n\n\n<tbody>\n\n<tr>\n<td class=\"poster-number2\" data-label=\"Poster:\"><a href=\"\/wp-content\/uploads\/2023\/12\/Kahlig_SYNGAP1-2023_Talk_Final.pdf\" target=\"_blank\">Progress Toward the Discovery of an ASO for Therapeutic Upregulation of SYNGAP1<\/a><\/td>\n\n<\/tr>\n\n\n<\/tbody>\n<\/table>\n\n<table class=\"poster-table2\"><colgroup> <col class=\"col-datetime\" \/>  <\/colgroup>\n<thead>\n\n<tr>\n<th class=\"date-header2\">2021 AES Annual Meeting<\/th>\n\n<\/tr>\n<\/thead>\n\n\n<tbody>\n\n<tr>\n<td class=\"poster-number2\" data-label=\"Poster:\"><a href=\"\/wp-content\/uploads\/2023\/09\/Jha_AES2021_poster_final.pdf\" target=\"_blank\">PRX-2904 is a Small Molecule Selective Inhibitor of KNa1.1 (KCNT1) that Reverses the ECoG Phenotype of a KCNT1 Gain-of-Function Mouse Model<\/a><\/td>\n\n<\/tr>\n\n\n<\/tbody>\n<\/table>\n\n<table class=\"poster-table2\"><colgroup> <col class=\"col-datetime\" \/>  <\/colgroup>\n<thead>\n\n<tr>\n<th class=\"date-header2\"><i>PAC-FOS in Epilepsia<\/i><\/th>\n\n<\/tr>\n<\/thead>\n\n\n<tbody>\n\n<tr>\n<td class=\"poster-number2\" data-label=\"Poster:\"><a href=\"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/epi.18592\" target=\"_blank\">PAC-FOS: A Novel Translational Concordance Framework Identifies Preclinical Seizure Models with Highest Predictive Validity for Clinical Focal Onset Seizures<\/a><\/td>\n\n<\/tr>\n\n\n<\/tbody>\n<\/table>\n<table class=\"poster-table2\"><colgroup> <col class=\"col-datetime\" \/>  <\/colgroup>\n<thead>\n\n<tr>\n<th class=\"date-header2\">PRX-2904 Chemistry in <i>ACS Medicinal Chemistry Letters<\/i><\/th>\n\n<\/tr>\n<\/thead>\n\n\n<tbody>\n\n<tr>\n<td class=\"poster-number2\" data-label=\"Poster:\"><a href=\"https:\/\/pubs.acs.org\/doi\/epdf\/10.1021\/acsmedchemlett.0c00675\" target=\"_blank\">Discovery of the First Orally Available, Selective KNa1.1 Inhibitor: In Vitro and In Vivo Activity of an Oxadiazole Series<\/a><\/td>\n\n<\/tr>\n\n<\/tbody>\n<\/table>\n\n\n\n<\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Scientific Publications &amp; Presentations\u00a0 Explore data from our clinical programs across central nervous system disorders, including movement disorders and epilepsy, supported by our precision neuroscience approach.\u00a0 Ulixacaltamide Relutrigine Vormatrigine Elsunersen Other 2026 AAN Annual Meeting Efficacy and Safety of Ulixacaltamide in Essential Tremor: Topline Phase 3 Results from Essential3 Study 1 (Parallel-Design Study) Maintenance of [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"inline_featured_image":false,"footnotes":"","_wpscppro_dont_share_socialmedia":false,"_wpscppro_custom_social_share_image":0,"_facebook_share_type":"","_twitter_share_type":"","_linkedin_share_type":"","_pinterest_share_type":"","_linkedin_share_type_page":"","_instagram_share_type":"","_medium_share_type":"","_threads_share_type":"","_google_business_share_type":"","_bluesky_share_type":"","_mastodon_share_type":"","_selected_social_profile":[],"_wpsp_enable_custom_social_template":false,"_wpsp_social_scheduling":{"enabled":false,"datetime":null,"platforms":[],"status":"template_only","dateOption":"today","timeOption":"now","customDays":"","customHours":"","customDate":"","customTime":"","schedulingType":"absolute"},"_wpsp_active_default_template":true},"class_list":["post-492","page","type-page","status-publish","hentry"],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 4.9.10 - aioseo.com -->\n\t<meta name=\"description\" content=\"Publications Scientific Publications &amp; Presentations Explore data from our clinical programs across central nervous system disorders, including movement disorders and epilepsy, supported by our precision neuroscience approach. Ulixacaltamide Relutrigine Vormatrigine Elsunersen Other 2026 AAN Annual Meeting Efficacy and Safety of Ulixacaltamide in Essential Tremor: Topline Phase 3 Results from Essential3 Study 1 (Parallel-Design Study) Maintenance\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<meta name=\"google-site-verification\" content=\"Hm7N4dIZbplFHb-2XqlOCgUkeRRYjj_g2S89FvbQjkE\" \/>\n\t<link rel=\"canonical\" href=\"https:\/\/praxismedicines.com\/cs\/publications\/\" \/>\n\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 4.9.10\" \/>\n\t\t<meta property=\"og:locale\" content=\"cs_CZ\" \/>\n\t\t<meta property=\"og:site_name\" content=\"Praxis Medicines - Dare for MORE\u2122\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"Publications - Praxis Medicines\" \/>\n\t\t<meta property=\"og:description\" content=\"Publications Scientific Publications &amp; Presentations Explore data from our clinical programs across central nervous system disorders, including movement disorders and epilepsy, supported by our precision neuroscience approach. Ulixacaltamide Relutrigine Vormatrigine Elsunersen Other 2026 AAN Annual Meeting Efficacy and Safety of Ulixacaltamide in Essential Tremor: Topline Phase 3 Results from Essential3 Study 1 (Parallel-Design Study) Maintenance\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/praxismedicines.com\/cs\/publications\/\" \/>\n\t\t<meta property=\"og:image\" content=\"https:\/\/praxismedicines.com\/wp-content\/uploads\/2025\/03\/social-1200x600-1.jpg\" \/>\n\t\t<meta property=\"og:image:secure_url\" content=\"https:\/\/praxismedicines.com\/wp-content\/uploads\/2025\/03\/social-1200x600-1.jpg\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2022-09-29T16:43:23+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2026-04-22T15:59:46+00:00\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:title\" content=\"Publications - Praxis Medicines\" \/>\n\t\t<meta name=\"twitter:description\" content=\"Publications Scientific Publications &amp; Presentations Explore data from our clinical programs across central nervous system disorders, including movement disorders and epilepsy, supported by our precision neuroscience approach. Ulixacaltamide Relutrigine Vormatrigine Elsunersen Other 2026 AAN Annual Meeting Efficacy and Safety of Ulixacaltamide in Essential Tremor: Topline Phase 3 Results from Essential3 Study 1 (Parallel-Design Study) Maintenance\" \/>\n\t\t<meta name=\"twitter:image\" content=\"https:\/\/praxismedicines.com\/wp-content\/uploads\/2025\/03\/astronaut-background-1400x350-1.jpg\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/praxismedicines.com\\\/cs\\\/publications\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/praxismedicines.com\\\/cs\\\/#listItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/praxismedicines.com\\\/cs\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/praxismedicines.com\\\/cs\\\/publications\\\/#listItem\",\"name\":\"Publications\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/praxismedicines.com\\\/cs\\\/publications\\\/#listItem\",\"position\":2,\"name\":\"Publications\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/praxismedicines.com\\\/cs\\\/#listItem\",\"name\":\"Home\"}}]},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/praxismedicines.com\\\/cs\\\/#organization\",\"name\":\"Praxis Medicines\",\"description\":\"Dare for MORE\\u2122\",\"url\":\"https:\\\/\\\/praxismedicines.com\\\/cs\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/praxismedicines.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/praxis-logos_full-color.svg\",\"@id\":\"https:\\\/\\\/praxismedicines.com\\\/cs\\\/publications\\\/#organizationLogo\",\"width\":432,\"height\":252},\"image\":{\"@id\":\"https:\\\/\\\/praxismedicines.com\\\/cs\\\/publications\\\/#organizationLogo\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/praxismedicines.com\\\/cs\\\/publications\\\/#webpage\",\"url\":\"https:\\\/\\\/praxismedicines.com\\\/cs\\\/publications\\\/\",\"name\":\"Publications - Praxis Medicines\",\"description\":\"Publications Scientific Publications & Presentations Explore data from our clinical programs across central nervous system disorders, including movement disorders and epilepsy, supported by our precision neuroscience approach. Ulixacaltamide Relutrigine Vormatrigine Elsunersen Other 2026 AAN Annual Meeting Efficacy and Safety of Ulixacaltamide in Essential Tremor: Topline Phase 3 Results from Essential3 Study 1 (Parallel-Design Study) Maintenance\",\"inLanguage\":\"cs-CZ\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/praxismedicines.com\\\/cs\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/praxismedicines.com\\\/cs\\\/publications\\\/#breadcrumblist\"},\"datePublished\":\"2022-09-29T16:43:23-04:00\",\"dateModified\":\"2026-04-22T11:59:46-04:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/praxismedicines.com\\\/cs\\\/#website\",\"url\":\"https:\\\/\\\/praxismedicines.com\\\/cs\\\/\",\"name\":\"Praxis Medicines\",\"description\":\"Dare for MORE\\u2122\",\"inLanguage\":\"cs-CZ\",\"publisher\":{\"@id\":\"https:\\\/\\\/praxismedicines.com\\\/cs\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"Publications - Praxis Medicines","description":"Publications Scientific Publications & Presentations Explore data from our clinical programs across central nervous system disorders, including movement disorders and epilepsy, supported by our precision neuroscience approach. Ulixacaltamide Relutrigine Vormatrigine Elsunersen Other 2026 AAN Annual Meeting Efficacy and Safety of Ulixacaltamide in Essential Tremor: Topline Phase 3 Results from Essential3 Study 1 (Parallel-Design Study) Maintenance","canonical_url":"https:\/\/praxismedicines.com\/cs\/publications\/","robots":"max-image-preview:large","keywords":"","webmasterTools":{"google-site-verification":"Hm7N4dIZbplFHb-2XqlOCgUkeRRYjj_g2S89FvbQjkE","miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BreadcrumbList","@id":"https:\/\/praxismedicines.com\/cs\/publications\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/praxismedicines.com\/cs\/#listItem","position":1,"name":"Home","item":"https:\/\/praxismedicines.com\/cs\/","nextItem":{"@type":"ListItem","@id":"https:\/\/praxismedicines.com\/cs\/publications\/#listItem","name":"Publications"}},{"@type":"ListItem","@id":"https:\/\/praxismedicines.com\/cs\/publications\/#listItem","position":2,"name":"Publications","previousItem":{"@type":"ListItem","@id":"https:\/\/praxismedicines.com\/cs\/#listItem","name":"Home"}}]},{"@type":"Organization","@id":"https:\/\/praxismedicines.com\/cs\/#organization","name":"Praxis Medicines","description":"Dare for MORE\u2122","url":"https:\/\/praxismedicines.com\/cs\/","logo":{"@type":"ImageObject","url":"https:\/\/praxismedicines.com\/wp-content\/uploads\/2025\/03\/praxis-logos_full-color.svg","@id":"https:\/\/praxismedicines.com\/cs\/publications\/#organizationLogo","width":432,"height":252},"image":{"@id":"https:\/\/praxismedicines.com\/cs\/publications\/#organizationLogo"}},{"@type":"WebPage","@id":"https:\/\/praxismedicines.com\/cs\/publications\/#webpage","url":"https:\/\/praxismedicines.com\/cs\/publications\/","name":"Publications - Praxis Medicines","description":"Publications Scientific Publications & Presentations Explore data from our clinical programs across central nervous system disorders, including movement disorders and epilepsy, supported by our precision neuroscience approach. Ulixacaltamide Relutrigine Vormatrigine Elsunersen Other 2026 AAN Annual Meeting Efficacy and Safety of Ulixacaltamide in Essential Tremor: Topline Phase 3 Results from Essential3 Study 1 (Parallel-Design Study) Maintenance","inLanguage":"cs-CZ","isPartOf":{"@id":"https:\/\/praxismedicines.com\/cs\/#website"},"breadcrumb":{"@id":"https:\/\/praxismedicines.com\/cs\/publications\/#breadcrumblist"},"datePublished":"2022-09-29T16:43:23-04:00","dateModified":"2026-04-22T11:59:46-04:00"},{"@type":"WebSite","@id":"https:\/\/praxismedicines.com\/cs\/#website","url":"https:\/\/praxismedicines.com\/cs\/","name":"Praxis Medicines","description":"Dare for MORE\u2122","inLanguage":"cs-CZ","publisher":{"@id":"https:\/\/praxismedicines.com\/cs\/#organization"}}]},"og:locale":"cs_CZ","og:site_name":"Praxis Medicines - Dare for MORE\u2122","og:type":"article","og:title":"Publications - Praxis Medicines","og:description":"Publications Scientific Publications &amp; Presentations Explore data from our clinical programs across central nervous system disorders, including movement disorders and epilepsy, supported by our precision neuroscience approach. Ulixacaltamide Relutrigine Vormatrigine Elsunersen Other 2026 AAN Annual Meeting Efficacy and Safety of Ulixacaltamide in Essential Tremor: Topline Phase 3 Results from Essential3 Study 1 (Parallel-Design Study) Maintenance","og:url":"https:\/\/praxismedicines.com\/cs\/publications\/","og:image":"https:\/\/praxismedicines.com\/wp-content\/uploads\/2025\/03\/social-1200x600-1.jpg","og:image:secure_url":"https:\/\/praxismedicines.com\/wp-content\/uploads\/2025\/03\/social-1200x600-1.jpg","article:published_time":"2022-09-29T16:43:23+00:00","article:modified_time":"2026-04-22T15:59:46+00:00","twitter:card":"summary_large_image","twitter:title":"Publications - Praxis Medicines","twitter:description":"Publications Scientific Publications &amp; Presentations Explore data from our clinical programs across central nervous system disorders, including movement disorders and epilepsy, supported by our precision neuroscience approach. Ulixacaltamide Relutrigine Vormatrigine Elsunersen Other 2026 AAN Annual Meeting Efficacy and Safety of Ulixacaltamide in Essential Tremor: Topline Phase 3 Results from Essential3 Study 1 (Parallel-Design Study) Maintenance","twitter:image":"https:\/\/praxismedicines.com\/wp-content\/uploads\/2025\/03\/astronaut-background-1400x350-1.jpg"},"aioseo_meta_data":{"post_id":"492","title":"#post_title #separator_sa #site_title","description":"#post_content","keywords":null,"keyphrases":null,"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_url":null,"og_image_width":null,"og_image_height":null,"og_image_custom_url":null,"og_image_custom_fields":null,"og_video":null,"og_custom_url":null,"og_article_section":null,"og_article_tags":null,"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_url":null,"twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_title":null,"twitter_description":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"","isEnabled":true},"graphs":[]},"schema_type":"default","schema_type_options":null,"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":null,"robots_max_videopreview":null,"robots_max_imagepreview":"large","priority":null,"frequency":null,"local_seo":null,"breadcrumb_settings":null,"limit_modified_date":false,"ai":null,"created":"2025-03-25 20:58:29","updated":"2026-04-22 17:42:03","seo_analyzer_scan_date":null},"aioseo_breadcrumb":"<div class=\"aioseo-breadcrumbs\"><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/praxismedicines.com\/cs\/\" title=\"Home\">Home<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\tPublications\n\t\t<\/span><\/div>","aioseo_breadcrumb_json":[{"label":"Home","link":"https:\/\/praxismedicines.com\/cs\/"},{"label":"Publications","link":"https:\/\/praxismedicines.com\/cs\/publications\/"}],"_links":{"self":[{"href":"https:\/\/praxismedicines.com\/cs\/wp-json\/wp\/v2\/pages\/492","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/praxismedicines.com\/cs\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/praxismedicines.com\/cs\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/praxismedicines.com\/cs\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/praxismedicines.com\/cs\/wp-json\/wp\/v2\/comments?post=492"}],"version-history":[{"count":0,"href":"https:\/\/praxismedicines.com\/cs\/wp-json\/wp\/v2\/pages\/492\/revisions"}],"wp:attachment":[{"href":"https:\/\/praxismedicines.com\/cs\/wp-json\/wp\/v2\/media?parent=492"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}